CLINICAL_TRIALS
withdrawal
· 2024-08-07
Clinical Trial Update: ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML [Phase 1]
Summary
A Phase 1 trial of ELU001 for CBFA2T3-GLIS2-positive pediatric acute myeloid leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Elucida Oncology | Conditions: Acute Myeloid Leukemia, AML, Childhood | Phase 1 | Status: WITHDRAWN